Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

321 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Vaccination against galectin-1 promotes cytotoxic T-cell infiltration in melanoma and reduces tumor burden.
Femel J, van Hooren L, Herre M, Cedervall J, Saupe F, Huijbers EJM, Verboogen DRJ, Reichel M, Thijssen VL, Griffioen AW, Hellman L, Dimberg A, Olsson AK. Femel J, et al. Among authors: reichel m. Cancer Immunol Immunother. 2022 Aug;71(8):2029-2040. doi: 10.1007/s00262-021-03139-4. Epub 2022 Jan 11. Cancer Immunol Immunother. 2022. PMID: 35018481 Free PMC article.
Correction to: Vaccination against galectin-1 promotes cytotoxic T-cell infiltration in melanoma and reduces tumor burden.
Femel J, van Hooren L, Herre M, Cedervall J, Saupe F, Huijbers EJM, Verboogen DRJ, Reichel M, Thijssen VL, Griffioen AW, Hellman L, Dimberg A, Olsson AK. Femel J, et al. Among authors: reichel m. Cancer Immunol Immunother. 2022 Oct;71(10):2581. doi: 10.1007/s00262-022-03175-8. Cancer Immunol Immunother. 2022. PMID: 35226107 Free PMC article. No abstract available.
Development of a novel therapeutic vaccine carrier that sustains high antibody titers against several targets simultaneously.
Saupe F, Reichel M, Huijbers EJ, Femel J, Markgren PO, Andersson CE, Deindl S, Danielson UH, Hellman LT, Olsson AK. Saupe F, et al. Among authors: reichel m. FASEB J. 2017 Mar;31(3):1204-1214. doi: 10.1096/fj.201600820R. Epub 2016 Dec 19. FASEB J. 2017. PMID: 27993994
VLRB vaccines fulfill several key criteria for an efficient therapeutic vaccine that targets self-antigens as a result of its small size, its multimerizing capacity, and nonexposed foreign sequences in the fusion protein.-Saupe, F., Reichel, M., Huijbers, E. J. M …
VLRB vaccines fulfill several key criteria for an efficient therapeutic vaccine that targets self-antigens as a result of its small size, it …
321 results